Aim: Evaluate prevalence of heart failure (HF) medications and their association with ventricular arrhythmia (VA) and survival among patients implanted with primary prevention implantable cardiac defibrillator (ICD)/cardiac resynchronization therapy + defibrillator (CRTD) devices. Methods: Association of treatment and dose (% guideline recommended target) of beta-adrenergic receptor antagonist (BB), angiotensin-antagonists (AngA), and mineralocorticoid-antagonists (MRA), after ICD/CRTD implant with VA and mortality was retrospectively analyzed. Results: Study included 186 HF patients; 42.5% and 57.5% implanted with ICD and CRTD, respectively. During 3.8 (2.1;6.7) years; 52 (28%) had VA and 77 (41.4%) died. Treatment (% of patients) included: BB (83%), AngA (87%), and MRA (59%). Median doses were 25(12.5;50)% of target for all medications. BB treatment >25% target dose was associated with reduced VA incidence. In the multivariable model including age, gender, diabetes, heart rate, and medication doses, increased BB dose was associated with reduced VA (hazard ratio (HR) 0.443 95% CI 0.222–0.885; p = 0.021). In the multivariable model for overall mortality including age, gender, renal disease, VA, and medical treatment, VA was associated with increased mortality (HR 2.672; 95% CI 1.429–4.999; p = 0.002) and AngA treatment was associated with reduced mortality (HR 0.515; 95% CI 0.285–0.929; p = 0.028). Conclusions: In this cohort of real-life HF patients discharged after ICD/CRTD implant, prevalence of guideline-based HF medications was high, albeit with low doses. Higher BB dose was associated with reduced VA, while AngA was associated with improved survival.
1 September 2019 in Journal Of Cardiovascular Emergencies
Background: Platelets play a pivotal role in the pathogenesis of acute coronary syndrome (ACS) and acute or chronic complications following percutaneous coronary intervention (PCI) as well. Platelet inhibition is a cornerstone treatment in the management of these patients. Thrombocytopenia in patients with ACS is uncommon. Idiopathic thrombocytopenic purpura (ITP) is a rare phenomenon; nevertheless, some case series presenting concomitant ACS and ITP have been described in the literature. The safety of antiplatelet therapy and PCI in patients who have ACS and thrombocytopenia is limited. Case summary: We present a case of a 60-year-old patient with ITP who was admitted with unstable angina pectoris. On admission, the platelet count was 23 × 109/L. Coronary CT angiography revealed severe stenosis in the mid portion of RCA. After one-week treatment with high-dose Prednisolone, the platelet count recovered, and coronary catheterization was performed. Successful PCI to the RCA with drug-eluting stent was performed. The patient was discharged on dual antiplatelet therapy. Conclusion: The case suggests that PCI is a suitable treatment for ITP patients with ACS. Hemostasis is the major concern in managing these patients. The treatment strategy may be based on platelet function rather than platelet count alone. Further analysis of antiplatelet therapies as mono or dual therapy are needed.
15 October 2026 in Frontiers in Cardiovascular Medicine
Background: SARS-CoV-2 has been linked to cardiovascular complications in the general population. However, data regarding cardiovascular outcomes among pregnant women remain limited, particularly in community-based ambulatory populations, as most previous studies focused primarily on hospitalized or critically ill patients. In this retrospective population-based matched cohort study, we evaluated whether COVID-19 infection during pregnancy is associated with an increased incidence of cardiovascular complications among pregnant women managed predominantly in outpatient settings. Methods: We conducted a retrospective population-based matched cohort study using electronic health record data from pregnant women between 2020 and 2025. Women with COVID-19 during pregnancy were matched 1:1 to women without documented COVID-19 during pregnancy according to demographic, obstetric, and clinical characteristics. The final analytical cohort included 4,068 women in each group. Cardiovascular outcomes during pregnancy and within a year since last menstrual period were assessed. Baseline demographic and obstetric characteristics were comparable between the COVID-19 and control groups. No significant differences were observed between the groups in the incidence of major cardiovascular complications, either when analyzed individually or as a composite endpoint (0.15% vs. 0.15%; OR 1.00, 95% CI 0.27–3.74). Specifically, there were no significant differences in the occurrence of atrial fibrillation/flutter, congestive heart failure, cardiomyopathy, myocarditis, pulmonary embolism, or deep venous thrombosis. In contrast, cough and backache were significantly more frequent among women with COVID-19 than among matched controls (6.88% vs. 4.87%; OR 1.45, 95% CI 1.19–1.75; 13.8% vs. 11.8%; OR 1.20, 95% CI 1.05–1.37; p = 0.007 respectively). Conclusions: Our findings suggest that among pregnant women in ambulatory community settings, COVID-19 infection is not associated with an increased risk of major cardiovascular complications.